Compare Crispr Therapeutics AG (CRSP) vs Live Nation Entertainment, Inc. (LYV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Live Nation Entertainment, Inc. — how do they compare? Crispr Therapeutics AG trades at $53.39 (market cap $4.88B), while Live Nation Entertainment, Inc. trades at $170.33 (market cap $39.92B). The key difference: Live Nation Entertainment, Inc. is far larger — about 8.2× Crispr Therapeutics AG's market cap, and Live Nation Entertainment, Inc. is trading nearer its 52-week high, Crispr Therapeutics AG nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and Live Nation Entertainment, Inc. for 72 Days on average.
| CRSP | LYV | |
|---|---|---|
Market Cap | $4.88B | $39.92B |
Volume | 2,861,747 | 1,982,609 |
Sector | Health | Media |
52-Week High | $74.92 | $188.46 |
52-Week Low | $44.34 | $125.61 |
Typical Hold Time | 77 Days | 72 Days |
Enterprise Value | $3.30B | $42.13B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $50.44, down 3.65% amid bearish technical signals. The company shows negative profitability with -$581.60M net income and -4,101.26% net margin for 2025, though Q2 2026 EPS beat expectations. Positive analyst sentiment persists with 57.9% buy ratings and $67.83 consensus target. Recent clinical data presentations and CASGEVY commercial progress provide catalysts.
The stock faces fundamental challenges with persistent losses and negative cash flow from operations, but maintains Wall Street support for its gene-editing pipeline. Key risks include clinical trial outcomes and cash burn, while potential upside hinges on successful drug commercialization and upcoming data readouts through 2026.
Live Nation Entertainment (LYV) trades at $171.34, up 0.29% with a bullish technical signal and strong analyst support. The company reported mixed Q2 2026 earnings with a beat on EPS but faces valuation concerns with a P/E of 117.49 and negative ROE of -116.65%. Recent news highlights strong consumer demand for live events and strategic partnerships, though insider selling and regulatory scrutiny present headwinds.
The outlook remains positive with 87% analyst buy ratings and a $208.18 price target, representing 21% upside. Key risks include high debt levels, margin pressure, and ongoing regulatory challenges. Revenue growth continues with 2026 projections of $26.3B, but profitability metrics need improvement for sustained shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Live Nation Entertainment, Inc.
Live Nation is the largest live entertainment firm in the world with over 570 million fans served in 44 countries in 2018 by the company's concert and ticketing platforms. Via either owning, operating, or holding exclusive booking rights, Live Nation controls over 235 venues including the House of Blues, the Hollywood Palladium, and Spark Arena in New Zealand. Live Nation also owns one of the largest ticketing services, Ticketmaster, which sold over 480 million tickets for over 12,000 clients in 2018. The firm's artist management agencies have over 400 clients. This large live entertainment footprint helped Live Nation become one of the largest advertising and sponsorship platforms aimed at music fans. Liberty Media owns 33% of Live Nation, held under its SiriusXM tracking stock.
Read more on LYV →
